Riyadh - Sharikat Mubasher: Sudair Pharmaceuticals Company (Sudair Pharma) signed a preliminary agreement with the Saudi National Unified Procurement Company (Nupco) and Sanofi Company to localize the manufacture of some insulin products in the Kingdom, the company unveiled in a statement.

 The agreement was signed during the Global Health Exhibition, under the auspices of Minister of Health, Fahad Al-Jalajel, Investment Minister, Khalid Al-Falih, and Minister of Industry, Bandar Al Khorayef.

Through this agreement, all parties aim to cover 90% of the Kingdom’s insulin needs, cement the Kingdom’s leading position in the medical and pharmaceutical industry, and develop the local content in the pharmaceutical industry field.

The agreement will participate in enlarging the benefit from the government purchasing power and reaching self-sufficiency in several priority products and sectors.

The Global Health Exhibition takes place in Riyadh from 29 to 31 October with the participation of more than 300 exhibitors from around the world.

It showcases innovations and products in various fields, including imaging and diagnosis, infrastructure, laboratory equipment and devices, medical equipment and devices, medicines, and nutrition, as well as information technology systems and solutions.